Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07789379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07789379 · ClinicalTrials.gov record · last posted 2026-08-27

Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma

Name: Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma — clinical trial record (NCT07789379)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorWei Jiang

Started2026-10-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will be enrolled. Subjects will be randomized 1:1 into Arm A (Adebrelimab + Temozolomide + Hyperbaric Oxygen Therapy) or Arm B (Adebrelimab + Temozolomide). The primary endpoint is progression-free survival(PFS). Secondary endpoints include overall survival(OS), objective response rate(ORR), disease control rate(DCR), change of KPS score, safety including TRAE, irAE and SAE. Exploratory objectives include correlation analysis between baseline clinical characteristics / hyperbaric-oxygen-related biomarkers and efficacy-safety outcomes.

Trial Details

NCT Number	NCT07789379
Lead Sponsor	Wei Jiang
Conditions	Glioblastoma
Enrollment	94 participants
Start Date	2026-10-01
Primary Completion	2028-10-01 (estimated)
Study Completion	2029-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-27